SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes - PubMed (original) (raw)
. 2004 May 25;101(21):8090-5.
doi: 10.1073/pnas.0308475101. Epub 2004 May 12.
Pin-Xian Xu, Derek Silvius, Edgar A Otto, Frank Beekmann, Ulla T Muerb, Shrawan Kumar, Thomas J Neuhaus, Markus J Kemper, Richard M Raymond Jr, Patrick D Brophy, Jennifer Berkman, Michael Gattas, Valentine Hyland, Eva-Maria Ruf, Charles Schwartz, Eugene H Chang, Richard J H Smith, Constantine A Stratakis, Dominique Weil, Christine Petit, Friedhelm Hildebrandt
Affiliations
- PMID: 15141091
- PMCID: PMC419562
- DOI: 10.1073/pnas.0308475101
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes
Rainer G Ruf et al. Proc Natl Acad Sci U S A. 2004.
Abstract
Urinary tract malformations constitute the most frequent cause of chronic renal failure in the first two decades of life. Branchio-otic (BO) syndrome is an autosomal dominant developmental disorder characterized by hearing loss. In branchio-oto-renal (BOR) syndrome, malformations of the kidney or urinary tract are associated. Haploinsufficiency for the human gene EYA1, a homologue of the Drosophila gene eyes absent (eya), causes BOR and BO syndromes. We recently mapped a locus for BOR/BO syndrome (BOS3) to human chromosome 14q23.1. Within the 33-megabase critical genetic interval, we located the SIX1, SIX4, and SIX6 genes, which act within a genetic network of EYA and PAX genes to regulate organogenesis. These genes, therefore, represented excellent candidate genes for BOS3. By direct sequencing of exons, we identified three different SIX1 mutations in four BOR/BO kindreds, thus identifying SIX1 as a gene causing BOR and BO syndromes. To elucidate how these mutations cause disease, we analyzed the functional role of these SIX1 mutations with respect to protein-protein and protein-DNA interactions. We demonstrate that all three mutations are crucial for Eya1-Six1 interaction, and the two mutations within the homeodomain region are essential for specific Six1-DNA binding. Identification of SIX1 mutations as causing BOR/BO offers insights into the molecular basis of otic and renal developmental diseases in humans.
Figures
Fig. 1.
Loss-of-function mutations detected in exons of the SIX1 gene of BOR/BO families F1038 (A), F1120 (B), and K6/7 (C), shown in relation to normal controls.
Fig. 2.
SIX1 mutations identified in BOR/BO patients affect protein–protein and protein–DNA interactions. Alignment of the Six-domain (SD) and homeodomain (HD) regions of mouse Six1, human SIX1–6, and the fly So proteins (GenBank accession nos. XP_138167, NP_005973, and NP_476733, respectively). Note that only a partial sequence of the SIX5 cDNA has been deposited in the databases. The tetrapeptides subdividing Six family proteins are boxed (22). Three SIX1 mutations (R110W, Y129C, and delE133) identified from BOR patients are circled. Amino acid position is numbered according to human SIX1 protein sequence. R110 and E133 are common to all Six proteins isolated so far, and Y129 is also found to be highly conserved among the Six1 gene products as well as the Drosophila so gene product.
Fig. 3.
(A) Yeast two-hybrid analysis. Cotransformants were analyzed for their ability to activate lacZ expression by liquid β-gal assay. Cotransformants of Gal4AD–Eya1D prey construct with pGBT9 vector alone was used as a negative control. Strength of interactions was judged by the units of β-gal activity. A result typical of three independent experiments (each performed in triplicate), which yielded essentially the same results, is shown with the standard deviation. (B) Gel-mobility shift assay. GST-fusion proteins of Six1 wild type and its mutants were incubated with a labeled multimerized (six copies) MEF3 motif (underlined). GST alone was incubated with the same DNA probe as a negative control. DNA probe alone was loaded onto the gel (lane 1). Arrow points to the shifted complex.
Fig. 4.
SIX1 mutations abolish the activation of myogenin promoter MEF3 by coexpression of Six1 and Eya1. The myogenin luciferase reporter pGL3–6×MEF3 was cotransfected with pcDNA3-Six1, pcDNA3-Six1-R110W, pcDNA3-Six1-Y129C, pcDNA3-Six1-delE133, pFlag-Eya1, or both the Six1 and Eya1 plasmids together in HEK293 cells. Luciferase activity in the cell lysate was normalized with β-gal activity of pCMVβ-gal as an internal control. The activity at each data point is relative to that obtained by the control pCMV vector. The mean fold activation from three independent experiments (each performed in duplicate) is shown with the standard deviation.
Similar articles
- SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent missense mutation associated with BOR.
Kochhar A, Orten DJ, Sorensen JL, Fischer SM, Cremers CW, Kimberling WJ, Smith RJ. Kochhar A, et al. Hum Mutat. 2008 Apr;29(4):565. doi: 10.1002/humu.20714. Hum Mutat. 2008. PMID: 18330911 - Molecular effects of Eya1 domain mutations causing organ defects in BOR syndrome.
Buller C, Xu X, Marquis V, Schwanke R, Xu PX. Buller C, et al. Hum Mol Genet. 2001 Nov 15;10(24):2775-81. doi: 10.1093/hmg/10.24.2775. Hum Mol Genet. 2001. PMID: 11734542 - Branchio-oto-renal syndrome: detection of EYA1 and SIX1 mutations in five out of six Danish families by combining linkage, MLPA and sequencing analyses.
Sanggaard KM, Rendtorff ND, Kjaer KW, Eiberg H, Johnsen T, Gimsing S, Dyrmose J, Nielsen KO, Lage K, Tranebjaerg L. Sanggaard KM, et al. Eur J Hum Genet. 2007 Nov;15(11):1121-31. doi: 10.1038/sj.ejhg.5201900. Epub 2007 Jul 18. Eur J Hum Genet. 2007. PMID: 17637804 - Branchio-oto-renal syndrome.
Kochhar A, Fischer SM, Kimberling WJ, Smith RJ. Kochhar A, et al. Am J Med Genet A. 2007 Jul 15;143A(14):1671-8. doi: 10.1002/ajmg.a.31561. Am J Med Genet A. 2007. PMID: 17238186 Review. - Branchio-oto-renal syndrome: comprehensive review based on nationwide surveillance in Japan.
Morisada N, Nozu K, Iijima K. Morisada N, et al. Pediatr Int. 2014 Jun;56(3):309-14. doi: 10.1111/ped.12357. Pediatr Int. 2014. PMID: 24730701 Review.
Cited by
- Pathogenic PHIP Variants are Variably Associated With CAKUT.
de Fallois J, Sieckmann T, Schönauer R, Petzold F, Münch J, Pauly M, Vasileiou G, Findeisen C, Kampmeier A, Kuechler A, Reis A, Decker E, Bergmann C, Platzer K, Tasic V, Kirschner KM, Shril S, Hildebrandt F, Chung WK, Halbritter J. de Fallois J, et al. Kidney Int Rep. 2024 May 27;9(8):2484-2497. doi: 10.1016/j.ekir.2024.05.024. eCollection 2024 Aug. Kidney Int Rep. 2024. PMID: 39156152 Free PMC article. - Genomic Landscape of Branchio-Oto-Renal Syndrome through Whole-Genome Sequencing: A Single Rare Disease Center Experience in South Korea.
Cho SH, Jeong SH, Choi WH, Lee SY. Cho SH, et al. Int J Mol Sci. 2024 Jul 26;25(15):8149. doi: 10.3390/ijms25158149. Int J Mol Sci. 2024. PMID: 39125727 Free PMC article. - CRISPR-based editing strategies to rectify EYA1 complex genomic rearrangement linked to haploinsufficiency.
Yi H, Yun Y, Choi WH, Hwang HY, Cha JH, Seok H, Song JJ, Lee JH, Lee SY, Kim D. Yi H, et al. Mol Ther Nucleic Acids. 2024 Apr 23;35(2):102199. doi: 10.1016/j.omtn.2024.102199. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38766525 Free PMC article. - Novel likely pathogenic variant in the EYA1 gene causing Branchio oto renal syndrome and the exploration of pathogenic mechanisms.
Zhang H, Gao J, Wang H, Liu M, Lu S, Xu H, Tang W, Zheng G. Zhang H, et al. BMC Med Genomics. 2024 Apr 16;17(1):89. doi: 10.1186/s12920-024-01858-y. BMC Med Genomics. 2024. PMID: 38627775 Free PMC article. - All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.
Hughes CJ, Alderman C, Wolin AR, Fields KM, Zhao R, Ford HL. Hughes CJ, et al. Biochim Biophys Acta Rev Cancer. 2024 May;1879(3):189098. doi: 10.1016/j.bbcan.2024.189098. Epub 2024 Mar 28. Biochim Biophys Acta Rev Cancer. 2024. PMID: 38555001 Review.
References
- Chan, J. C., Williams, D. M. & Roth, K. S. (2002) Pediatr. Rev. 23, 47–60. - PubMed
- Melnick, M., Bixler, D., Nance, W. E., Silk, K. & Yune, H. (1976) Clin. Genet. 9, 25–34. - PubMed
- Abdelhak, S., Kalatzis, V., Heilig, R., Compain, S., Samson, D., Vincent, C., Levi-Acobas, F., Cruaud, C., Le Merrer, M., Mathieu, M., et al. (1997) Hum. Mol. Genet. 6, 2247–2255. - PubMed
- Abdelhak, S., Kalatzis, V., Heilig, R., Compain, S., Samson, D., Vincent, C., Weil, D., Cruaud, C., Sahly, I., Leibovici, M., et al. (1997) Nat. Genet. 15, 157–164. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DC003544/DC/NIDCD NIH HHS/United States
- R01-DK64640/DK/NIDDK NIH HHS/United States
- 1 R01-DE14090-01/DE/NIDCR NIH HHS/United States
- R01 DC005824/DC/NIDCD NIH HHS/United States
- R01 DE014090/DE/NIDCR NIH HHS/United States
- R01 DK064640/DK/NIDDK NIH HHS/United States
- R01-DC05824/DC/NIDCD NIH HHS/United States
- R01-DC03544/DC/NIDCD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous